Vancouver, British Columbia, March 31st, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it is has filed a pre-IND (Investigational New Drug) meeting request and submitted a briefing package with the US Food and Drug Administration (FDA), Center […]

Vancouver, British Columbia, March 15th, 2021 —  BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it has entered into a major bioproduction agreement with WuXi Biologics Ltd. (“WuXi Bio”), a leading global Contract Development and Manufacturing Organization (“CDMO”) to produce […]

BVX-0320 and Covid-T to have capability to address UK, Brazilian and South African Virus Variants Vancouver, British Columbia March 1st, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it is assessing steps to modify BVX-0320 and Covid-T, its […]

Vancouver, British Columbia, February 16TH, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys” or “Company”) is pleased to announce that the company has been approved for DTCC full service eligibility in the United States and its shares are qualified to be held at the Depository Trust Company (“DTC”) and traded and serviced through […]

USD$900,000 In-Kind Investment by Procare Health into Phase I Clinical Study for BVX-0918A in the EU Co-Development of Vaccines for Cervical Cancer and HPV Right of First Refusal for US Marketing of Papilocare™ Vancouver, British Columbia and Barcelona, Spain, February 10th, 2021 —  BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”), the world leader in […]

Features Observation of Neutralizing Antibodies to SARS-CoV-2 Advancement of Viral Vaccine Platform and T-cell Diagnostic to Address Emerging SARS-CoV-2 Strains BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (“BioVaxys” or “Company”) is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021. BioVaxys […]

Titer Analysis Confirms 100% Efficacy at All Higher Dose Levels in Murine Mouse Study; Preclinical Data Supports Expansion of Vaccine Platform Across Range of Viral Diseases Vancouver, British Columbia–(Newsfile Corp. – November 30, 2020) – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (“BioVaxys” or “the Company”) is pleased to announce that it has received further […]

Vancouver, British Columbia, November 10, 2020 —  BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB) (“BioVaxys”) is pleased to announce that results from its preclinical animal study (also known as the “murine model study”) of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein.  Previous interim data […]

VANCOUVER, BC ― November 2, 2020 ― BioVaxys Technology Corp. CSE: BIOV; “BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related […]

October 26,     2020      Vancouver, British Columbia  BioVaxys Technology Corp. (CSE: BIOV), is pleased to announce that it has entered into a research collaboration with The Ohio State University (“OSU”) for BioVaxys’ SARS-CoV-2 vaccine candidate. OSU is a leading global academic research institute in the fight against SARS-CoV-2, with The Ohio State University Wexner Medical Center […]